Diversified Healthcare Trust (DHC) has been rated a 'Buy' due to improved fundamentals and a stronger balance sheet despite recent share price gains. In Q2 2026, its SHOP segment's net operating income rose 37.2% year-over-year, with normalized funds from operations (FFO) surging 109.4% to $0.16 per share. The company has successfully reduced leverage, with net debt to adjusted EBITDAre falling to 7.1x, no major debt maturities until 2028, and $270 million in liquidity. DHC prioritizes balance sheet strength over dividends, supported by SHOP segment growth and a supply-demand imbalance, making it an attractive investment opportunity.
Stifel Nicolaus has reiterated a Buy rating for Accenture with a price target of $242, reflecting confidence in the company's strong recent stock performance and growth prospects. Accenture's shares rose 13.4% in the month leading up to October 15, 2...
Investment firm William Blair downgraded CCC Intelligent Solutions to Market Perform amid news of a $6.1 billion acquisition by a consortium led by GTCR and Elliott Investment Management. Shareholders will receive $7.75 per share, a premium over rece...
U.S. Bancorp reported third-quarter 2026 earnings per share of $1.34, exceeding analyst estimates of $1.32 and marking its fourth consecutive earnings beat. Revenue grew 8.8% year-over-year to $7.97 billion but fell just short of the $8.00 billion ex...
Vallourec, a global leader in premium tubular solutions, will showcase its VAM® product line and the expanded CLEANWELL® grease-free range at ADIPEC 2026 in Abu Dhabi. These offerings aim to enhance operational efficiency and support energy transitio...
At ADIPEC 2026 in Abu Dhabi, Vallourec showcased its VAM® portfolio and the expanded CLEANWELL® range, highlighting innovations that improve operational efficiency and reduce environmental impact in the energy sector. The VAM® connections cater to oi...
